CTRC Antibody / Chymotrypsin C, 100 ug

CTRC antibody detects Chymotrypsin C, a digestive serine protease that regulates pancreatic enzyme activation and degradation. Encoded by the CTRC gene on chromosome 1p36.21, this enzyme is secreted by pancreatic acinar cells and plays a dual role in digestive proteolysis and zymogen activation control. CTRC contributes to the post-translational activation of trypsinogen and other pancreatic proteases while simultaneously degrading prematurely activated trypsin to prevent autodigestion and pancreatitis.

Structurally, Chymotrypsin C is synthesized as an inactive zymogen (chymotrypsinogen C) and activated by proteolytic cleavage in the small intestine. The mature enzyme is approximately 29 kilodaltons and contains a catalytic triad (His, Asp, Ser) characteristic of serine proteases. CTRC exhibits substrate specificity distinct from other chymotrypsins, favoring cleavage after bulky hydrophobic residues and acting on peptide bonds within pancreatic proenzymes and regulatory proteins.

The CTRC antibody is widely used in digestive biology, enzymology, and pancreatic disease research to study protease regulation, secretion, and zymogen activation. Western blot analysis detects a 29 kilodalton band corresponding to the active enzyme, while immunohistochemistry reveals cytoplasmic staining in pancreatic acinar cells. This antibody supports research on digestive enzyme control, pancreatitis pathogenesis, and exocrine pancreas physiology.

Mutations in CTRC are associated with hereditary chronic pancreatitis and idiopathic pancreatic inflammation, where loss of enzyme function impairs trypsin degradation, leading to excessive intrapancreatic activation. CTRC variants can also affect digestive efficiency and susceptibility to pancreatic stress. Beyond digestion, CTRC influences the proteolytic processing of hormones and growth factors, expanding its role in systemic protease regulation. The CTRC antibody provides a reliable tool for studying enzyme expression, activity regulation, and genetic variants linked to pancreatic disease. NSJ Bioreagents validates this antibody for its applications, ensuring accurate detection for digestive and enzymatic research.